PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Salmon provides fast and bias-aware quantification of transcript expression
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., & Kingsford, C. (2017) · Nature Methods · doi:10.1038/nmeth.4197 · Cited by 12,700
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576
Li, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S., Brown, M., & Liu, X. S. (2014) · Genome Biology · doi:10.1186/s13059-014-0554-4 · Cited by 2,684
cGAS surveillance of micronuclei links genome instability to innate immunity
Mackenzie, K. J., Carroll, P., Martin, C.-A., Murina, O., Fluteau, A., Simpson, D. J., Olova, N., Sutcliffe, H., Rainger, J. K., Leitch, A., et al. (2017) · Nature · doi:10.1038/nature23449 · Cited by 1,752 · cited 5×
“A growing body of literature suggests that one of the consequences of genetic instability in cancer is the presence of aberrant nucleic acids in the cytosol (Paludan et al., 2019; Hatch et al., 2013; Harding et al., 2017; Mackenzie et al., 2017; Gluck et al., 2017).”
BackgroundInfluentialCorrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
Mitotic progression following DNA damage enables pattern recognition within micronuclei
Harding, S. M., Benci, J. L., Irianto, J., Discher, D. E., Minn, A. J., & Greenberg, R. A. (2017) · Nature · doi:10.1038/nature23470 · Cited by 1,508
STING: infection, inflammation and cancer.
Barber, G. N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3921 · Cited by 1,313 · cited 3×
“…sensing mechanisms through cGAS/STING and RIG-I, activate type I IFNs to induce innate immunity in response to pathogenor damage-generated cytosolic nucleic acids (Ivashkiv and Donlin, 2014; Paludan et al., 2019; Barber, 2015; Ishikawa and Barber, 2008; Ahn et al., 2014; Hartlova et al., 2015).”
BackgroundType I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence
Glück, S., Guey, B., Gulen, M. F., Wolter, K., Kang, T.-W., Schmacke, N. A., Bridgeman, A., Rehwinkel, J., Zender, L., & Ablasser, A. (2017) · Nature Cell Biology · doi:10.1038/ncb3586 · Cited by 1,196 · cited 5×
“A growing body of literature suggests that one of the consequences of genetic instability in cancer is the presence of aberrant nucleic acids in the cytosol (Paludan et al., 2019; Hatch et al., 2013; Harding et al., 2017; Mackenzie et al., 2017; Gluck et al., 2017).”
BackgroundInfluentialTargeting STING with covalent small-molecule inhibitors
Haag, S. M., Gulen, M. F., Reymond, L., Gibelin, A., Abrami, L., Decout, A., Heymann, M., van der Goot, F. G., Turcatti, G., Behrendt, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0287-8 · Cited by 1,178
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852 · cited 1×
“In a recent genetic screen to identify tumor factors that suppress T cell activation, PARP7 was identified as a significant gene hit (Pan et al., 2018).”
BackgroundSelf-citationQuintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood · doi:10.1182/blood-2009-04-214957 · Cited by 843 · cited 3×
“RBN-2397 antitumor immunity is dependent on tumorproduced type I IFN signaling To investigate the mechanism of RBN-2397 in restoring type I IFN signaling, we used pharmacological inhibitors BX795 for TBK1 (Clark et al., 2009), C-178 for STING (Haag et al., 2018), and ruxolitinib for JAK1/2 (Quintas-Cardama et al., 201…”
BackgroundMethodPantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743
Catastrophic nuclear envelope collapse in cancer cell micronuclei
Hatch, E. M., Fischer, A. H., Deerinck, T. J., & Hetzer, M. W. (2013) · Cell · doi:10.1016/j.cell.2013.06.007 · Cited by 741 · cited 5×
“A growing body of literature suggests that one of the consequences of genetic instability in cancer is the presence of aberrant nucleic acids in the cytosol (Paludan et al., 2019; Hatch et al., 2013; Harding et al., 2017; Mackenzie et al., 2017; Gluck et al., 2017).”
BackgroundInfluentialHärtlova, A., Erttmann, S. F., Raffi, F. A., Schmalz, A. M., Resch, U., Anugula, S., Lienenklaus, S., Nilsson, L. M., Kröger, A., Nilsson, J. A., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.012 · Cited by 716 · cited 3×
“…sensing mechanisms through cGAS/STING and RIG-I, activate type I IFNs to induce innate immunity in response to pathogenor damage-generated cytosolic nucleic acids (Ivashkiv and Donlin, 2014; Paludan et al., 2019; Barber, 2015; Ishikawa and Barber, 2008; Ahn et al., 2014; Hartlova et al., 2015).”
BackgroundPARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer
Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.054 · Cited by 572 · cited 1×
“In this context, PARP1 inhibitors have been shown to trigger antitumor immune responses in preclinical BRCA-deficient mouse models (Pantelidou et al., 2019; Shen et al., 2019; Ding et al., 2018).”
BackgroundPharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles
Vanpouille-Box, C., Hoffmann, J. A., & Galluzzi, L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0043-2 · Cited by 183
CRISPR Approaches to Small Molecule Target Identification
Jost, M., & Weissman, J. S. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00965 · Cited by 88 · cited 1×
“Type I IFN pathway genes confer resistance and sensitivity to RBN-2397 for proliferation To further explore how RBN-2397 inhibits NCI-H1373 cell proliferation, we performed unbiased genetic screens using wholegenome CRISPRi and CRISPRa libraries (le Sage et al., 2017; Jost and Weissman, 2018).”
Method
Cited by
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Metadata
- Authors
- Gozgit, J. M., Vasbinder, M. M., Abo, R. P., Kunii, K., Kuplast-Barr, K. G., Gui, B., Lu, A. Z., Molina, J. R., Minissale, E., Swinger, K. K., Wigle, T. J., Blackwell, D. J., Majer, C. R., Ren, Y., Niepel, M., Varsamis, Z. A., Nayak, S. P., Bamberg, E., Mo, J.-R., Church, W. D., Mady, A. S. A., Song, J., Utley, L., Rao, P. E., Mitchison, T. J., Kuntz, K. W., Richon, V. M., & Keilhack, H.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 39
- Issue
- 9
- Pages
- 1214-1226.e10
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W3186610389
- Cited by
- 181
- References
- 19
- FWCI
- 8.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.